Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes

Obiettivo

"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure acute myeloid leukemia (AML) via the immunological graft-versus-leukemia (GVL) effect, but relapse through immune evasion is frequent and accounts for 50% of the allo-HSCT-related mortality. The current strategy for relapse relies on chemo- or targeted therapy combined with donor lymphocyte infusions. Still, only few patients achieve long-term cure, underlining the urgent need for a better mechanistic understanding and more effective treatments.

Our recent work indicates that metabolic adaptations in AML—induced by prior chemotherapy exposure—act as protective ""shields"" against anti-leukemia immunity. Notably, we identified the bioactive lipids phosphatidic acid (PA) and oxylipins as two such shields. With LIFE, we will test the concept that selected bioactive lipids drive AML relapse—and that blocking them can enhance the GVL response and improve allo-HSCT outcomes.

We will integrate lipidomics for bioactive lipid detection, spatial and single-cell technologies, and functional genomics with in vivo allo-HSCT models and primary human AML samples to define the molecular effects of PA (Aim 1) and oxylipins (Aim 2) on immune evasion. Importantly, we will test how targeting these axes synergizes with donor immune cells and improves leukemia control. In parallel, we will use focused in vitro and in vivo CRISPRi screens to discover lipid pathway genes whose inhibition sensitizes AML to combined chemo-immune pressure (Aim 3).

This project will, for the first time, delineate how AML-derived bioactive lipids orchestrate immune evasion and provide a rationale for combinations targeting these pathways to improve allo-HSCT outcomes. Beyond allo-HSCT, we will uncover fundamental principles of how bioactive lipids shape tumor–immune interactions. By turning the metabolic shields into vulnerabilities, LIFE will deliver novel entry points for next-generation cancer therapies.
"

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-STG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITAT BASEL
Contributo netto dell'UE
€ 1 499 511,00
Indirizzo
PETERSPLATZ 1
4051 Basel
Svizzera
Regione
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 499 511,00

Beneficiari (1)